Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.

about

Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab.

P2860

Q55100888-EF5E9B1E-88DD-498D-A9BF-22A800B18986

P2860

Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.

Item

http://www.wikidata.org/entity/Q47688850

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Efficacy and safety of retreat ...... iously treated with nivolumab.

@en

Efficacy and safety of retreat ...... iously treated with nivolumab.

@nl

type

Item

label

Efficacy and safety of retreat ...... iously treated with nivolumab.

@en

Efficacy and safety of retreat ...... iously treated with nivolumab.

@nl

prefLabel

Efficacy and safety of retreat ...... iously treated with nivolumab.

@en

Efficacy and safety of retreat ...... iously treated with nivolumab.

@nl

P1476

Efficacy and safety of retreat ...... iously treated with nivolumab.

@en

P2093

Hiroki Nagai

http://www.w3.org/2001/XMLSchema#string

Manabu Muto

http://www.w3.org/2001/XMLSchema#string

Shigemi Matsumoto

http://www.w3.org/2001/XMLSchema#string

Tomohiro Kondo

http://www.w3.org/2001/XMLSchema#string

Yo Kaku

http://www.w3.org/2001/XMLSchema#string

Yumi Nonomura

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.

P2888

s00280-017-3444-0

P304

999-1004

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-017-3444-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Motoo Nomura

Atsushi Otsuka

P577

2017-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28983657

http://www.w3.org/2001/XMLSchema#string

Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.

about

P2860

P2860

Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698